Azenta, Inc. at the moment introduced that it has closed its beforehand introduced sale of B Medical Techniques S.á r.l (BMS) to Thelema S.a r l. The transaction was initially introduced on December 29, 2025, and closed on July 1, 2026, following the satisfaction of all closing circumstances, together with Thelema’s completion of its financing preparations. Beneath the phrases of the settlement, Azenta bought B Medical Techniques for a hard and fast buy value of $63 million in money, of which $35 million was funded via a short-term secured vendor mortgage from an Azenta subsidiary to Thelema.
As a part of the transaction, Whitestone group, a Belgian publicly listed funding holding firm (Euronext Development: ROCK) has acquired a 40% stake in B Medical Techniques via Thelema S.a r.l, a Particular Goal Car (SPV) established for the acquisition of B Medical Techniques. Whitestone group, which focuses on investing in established SMEs in Luxembourg and Belgium with a deal with well being, optical, and industrial sectors, has invested $19 million (∼EUR 17 million), together with a portion within the type of a subordinated mortgage, to amass 40% of BMS alongside the CEO of BMS, Mr. Luc Provost, who will maintain the vast majority of the capital below the LMBO.
The acquisition of B Medical Techniques matches completely with our technique and the group’s funding standards: a European industrial firm, positioned in high-value-added merchandise and guarded by sturdy limitations to entry, pushed by high quality administration and a significant mission. In it we discover all the standards we search for in our personal fairness holdings. I wish to thank Luc Provost for the belief he has positioned in us to help him on this new stage of the corporate’s growth.”
Mr. Frédéric Pouchain, CEO, Whitestone Group
“I wish to warmly thank Whitestone Group for putting its belief in me after I introduced my plan to amass BMS, an organization I’ve labored for over 27 years and led for 11 years. This MBO is a brand new chapter within the lifetime of the corporate, which regains a close-knit, entrepreneurial shareholder base. I’m assured within the success of the diversification initiated in direction of the protection and meals chain sectors, which provide enticing progress prospects. Lastly, reaching compliance with the newest WHO requirements throughout our total new vaccine chilly chain product vary marks a major milestone, reinforcing our dedication to supporting immunization and healthcare packages worldwide. B Medical Techniques is considered one of Luxembourg’s bigger industrial firms, and my ambition just isn’t solely to protect that place but additionally to construct on it and drive the corporate’s continued progress and success,” mentioned Mr. Luc Provost, CEO of B Medical Techniques.
